Zura Bio Announces Updates on Tibulizumab Programs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Zura Bio announced several tibulizumab program updates. Zura has completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with HS. The TibuSHIELD trial exceeded the target enrollment, with 247 participants enrolled. Zura remains on track to complete enrollment of the Phase 2 TibuSURE trial of tibulizumab in adults with early diffuse cutaneous SSc in early July. The TibuSURE trial has already exceeded the target enrollment of 80 participants. Exceeding enrollment targets in both TibuSHIELD and TibuSURE reflects the significant unmet need facing patients with HS and SSc. Topline data from TibuSHIELD are expected in the fourth quarter of 2026. Topline data from TibuSURE are expected in H1 2027. Building on tibulizumab's bispecific mechanism targeting both interleukin-17 and B cell activating factor, Zura plans to initiate a Phase 2 study in a third immune-mediated indication by year end 2026. Indication expansion of tibulizumab reflects Zura's belief in the broad potential of IL-17 and BAFF dual pathway inhibition across immune-mediated diseases. Zura plans to announce the new indication prior to study initiation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZURA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZURA
Wall Street analysts forecast ZURA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.360
Low
15.00
Averages
16.50
High
18.00
Current: 5.360
Low
15.00
Averages
16.50
High
18.00
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenaya Therapeutics Appoints New CFO Eric Hyllengren
- Executive Change: Tenaya Therapeutics has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, succeeding Hiro Higa, who will retire in Q3 2026; Hyllengren brings over 20 years of biotech finance experience and will oversee the company's financial strategy and capital allocation.
- Previous Experience: Most recently, Hyllengren served as CFO and Executive Vice President at Zura Bio Limited, and prior to that, he was CFO and COO at Atara Biotherapeutics, where he successfully led public financing activities and guided the company's organizational transformation.
- Transition Plan: Tenaya stated that Higa's retirement is unrelated to Hyllengren's appointment, and Higa will remain with the company as a consultant to facilitate the transition of finance and accounting responsibilities, ensuring continuity in operations.
- Stock Performance: Tenaya Therapeutics' stock has traded between $0.53 and $2.35 over the past year, closing at $0.73 on Monday with a 2.43% increase, although shares are trading down 0.76% to $0.72 in the overnight market, indicating that market reactions to the new CFO will need to be monitored.
See More
Zura Bio Updates on Tibulizumab Clinical Progress
- Enrollment Success: Zura has successfully enrolled 247 participants in the TibuSHIELD trial, exceeding its target, which highlights the significant unmet need among patients with moderate to severe HS, with topline data expected in Q4 2026 potentially boosting stock performance.
- SSc Trial Progress: The TibuSURE trial has surpassed its enrollment target of 80 participants and is on track to complete enrollment by early July, with topline data anticipated in H1 2027, further validating the market potential of tibulizumab.
- New Indication Study Plans: Zura plans to initiate a Phase 2 study for a third immune-mediated indication by the end of 2026, reflecting the company's confidence in the dual-target mechanism of tibulizumab, which may broaden its market applications.
- Strong Financial Position: As of March 31, 2026, Zura reported cash and cash equivalents of $225.6 million, which is expected to fund operations through at least the end of 2028, ensuring sufficient capital for ongoing clinical development.
See More
Zura Bio Grants Stock Options to New CBO
- Executive Appointment and Incentive: On May 13, 2026, Zura Bio granted an option to purchase 600,000 Class A Ordinary Shares to new Chief Business Officer Muzammil Mustufa, reflecting the company's commitment to attracting and retaining key talent in leadership roles.
- Option Details: The option has an exercise price of $4.80 per share, equal to the closing price on the grant date, and will vest over four years, with one-fourth vesting on the first anniversary and the remainder in quarterly installments, ensuring Mustufa's continuous service.
- Company Background: Zura Bio is a clinical-stage biotechnology firm focused on developing novel medicines for autoimmune and inflammatory diseases, aiming to significantly improve patient quality of life, which holds substantial market potential.
- Pipeline Progress: Zura's lead candidate, tibulizumab, is undergoing two Phase 2 clinical studies targeting hidradenitis suppurativa and systemic sclerosis, demonstrating the company's proactive exploration in addressing unmet medical needs in the therapeutic landscape.
See More
Zura Bio Appoints New Chief Business Officer
- Executive Appointment: Zura Bio has appointed Muzammil Mustufa as Chief Business Officer, overseeing corporate strategy, business development, and investor relations, which is expected to enhance the company's clinical and commercialization capabilities.
- Diverse Experience: Mustufa brings 20 years of pharmaceutical and biotechnology experience, having served as Vice President of Corporate Strategy at Amicus Therapeutics, where he played a key role in the global launch of two orphan disease drugs, showcasing his strong background in immunology and rare diseases.
- Product Development Outlook: Zura's lead candidate tibulizumab is currently undergoing two Phase 2 clinical studies, and Mustufa's addition is anticipated to accelerate product development, enhancing the company's competitiveness in the autoimmune disease market.
- Strategic Vision: Mustufa expressed excitement about contributing during a pivotal time for Zura, emphasizing the potential of tibulizumab as a first-in-class bispecific antibody to improve treatment outcomes for patients with complex immune disorders, further driving the company's growth.
See More
Zura Biopress Reports Q1 2026 Financial Results
- Financial Performance: Zura Biopress reported a Q1 2026 GAAP EPS of -$0.22, indicating ongoing challenges in profitability, although cash and cash equivalents reached $225.6 million, expected to fund operations through at least the end of 2028.
- Expense Increase: General and administrative expenses rose to $10.8 million in Q1 2026 from $8.8 million in Q1 2025, primarily due to increased compensation and professional fees, reflecting the company's investment in supporting its clinical programs and overall growth.
- Public Offering Plans: Zura Bio is seeking to raise $125 million through a public offering to support future R&D and operations, despite a GAAP EPS of -$1.06 that missed expectations, raising concerns about its financial health in the market.
- Market Evaluation: According to Seeking Alpha's Quant Rating, Zura Bio's momentum is considered real, but the successful delivery of its TibuSHIELD project remains critical, which will directly impact investor confidence in the company's future prospects.
See More
Zura Bio Reports Q1 2026 Financial Results and Updates
- Clinical Trial Progress: Zura Bio's two ongoing Phase 2 trials, TibuSHIELD and TibuSURE, are on track to report topline data in Q4 2026 and H1 2027, respectively, indicating the company's commitment to advancing its pipeline and capturing market opportunities.
- Strong Cash Position: As of March 31, 2026, Zura reported cash and cash equivalents of $225.6 million, which is expected to fund operations through at least the end of 2028, reflecting robust financial management and confidence in future growth.
- Leadership Appointments: In January 2026, Sandeep Kulkarni was appointed CEO, followed by the addition of two board members in February, enhancing the company's leadership team to drive strategic development in the biotechnology sector.
- Financial Performance: Zura reported a net loss of $24.2 million for Q1 2026, up from $17.4 million in Q1 2025, primarily due to increased R&D expenses, highlighting the ongoing investment and challenges in clinical development.
See More
Tenaya Therapeutics Appoints New CFO Eric Hyllengren
- Executive Change: Tenaya Therapeutics has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, succeeding Hiro Higa, who will retire in Q3 2026; Hyllengren brings over 20 years of biotech finance experience and will oversee the company's financial strategy and capital allocation.
- Previous Experience: Most recently, Hyllengren served as CFO and Executive Vice President at Zura Bio Limited, and prior to that, he was CFO and COO at Atara Biotherapeutics, where he successfully led public financing activities and guided the company's organizational transformation.
- Transition Plan: Tenaya stated that Higa's retirement is unrelated to Hyllengren's appointment, and Higa will remain with the company as a consultant to facilitate the transition of finance and accounting responsibilities, ensuring continuity in operations.
- Stock Performance: Tenaya Therapeutics' stock has traded between $0.53 and $2.35 over the past year, closing at $0.73 on Monday with a 2.43% increase, although shares are trading down 0.76% to $0.72 in the overnight market, indicating that market reactions to the new CFO will need to be monitored.
See More
Zura Bio Updates on Tibulizumab Clinical Progress
- Enrollment Success: Zura has successfully enrolled 247 participants in the TibuSHIELD trial, exceeding its target, which highlights the significant unmet need among patients with moderate to severe HS, with topline data expected in Q4 2026 potentially boosting stock performance.
- SSc Trial Progress: The TibuSURE trial has surpassed its enrollment target of 80 participants and is on track to complete enrollment by early July, with topline data anticipated in H1 2027, further validating the market potential of tibulizumab.
- New Indication Study Plans: Zura plans to initiate a Phase 2 study for a third immune-mediated indication by the end of 2026, reflecting the company's confidence in the dual-target mechanism of tibulizumab, which may broaden its market applications.
- Strong Financial Position: As of March 31, 2026, Zura reported cash and cash equivalents of $225.6 million, which is expected to fund operations through at least the end of 2028, ensuring sufficient capital for ongoing clinical development.
See More
Zura Bio Grants Stock Options to New CBO
- Executive Appointment and Incentive: On May 13, 2026, Zura Bio granted an option to purchase 600,000 Class A Ordinary Shares to new Chief Business Officer Muzammil Mustufa, reflecting the company's commitment to attracting and retaining key talent in leadership roles.
- Option Details: The option has an exercise price of $4.80 per share, equal to the closing price on the grant date, and will vest over four years, with one-fourth vesting on the first anniversary and the remainder in quarterly installments, ensuring Mustufa's continuous service.
- Company Background: Zura Bio is a clinical-stage biotechnology firm focused on developing novel medicines for autoimmune and inflammatory diseases, aiming to significantly improve patient quality of life, which holds substantial market potential.
- Pipeline Progress: Zura's lead candidate, tibulizumab, is undergoing two Phase 2 clinical studies targeting hidradenitis suppurativa and systemic sclerosis, demonstrating the company's proactive exploration in addressing unmet medical needs in the therapeutic landscape.
See More
Zura Bio Appoints New Chief Business Officer
- Executive Appointment: Zura Bio has appointed Muzammil Mustufa as Chief Business Officer, overseeing corporate strategy, business development, and investor relations, which is expected to enhance the company's clinical and commercialization capabilities.
- Diverse Experience: Mustufa brings 20 years of pharmaceutical and biotechnology experience, having served as Vice President of Corporate Strategy at Amicus Therapeutics, where he played a key role in the global launch of two orphan disease drugs, showcasing his strong background in immunology and rare diseases.
- Product Development Outlook: Zura's lead candidate tibulizumab is currently undergoing two Phase 2 clinical studies, and Mustufa's addition is anticipated to accelerate product development, enhancing the company's competitiveness in the autoimmune disease market.
- Strategic Vision: Mustufa expressed excitement about contributing during a pivotal time for Zura, emphasizing the potential of tibulizumab as a first-in-class bispecific antibody to improve treatment outcomes for patients with complex immune disorders, further driving the company's growth.
See More
Zura Biopress Reports Q1 2026 Financial Results
- Financial Performance: Zura Biopress reported a Q1 2026 GAAP EPS of -$0.22, indicating ongoing challenges in profitability, although cash and cash equivalents reached $225.6 million, expected to fund operations through at least the end of 2028.
- Expense Increase: General and administrative expenses rose to $10.8 million in Q1 2026 from $8.8 million in Q1 2025, primarily due to increased compensation and professional fees, reflecting the company's investment in supporting its clinical programs and overall growth.
- Public Offering Plans: Zura Bio is seeking to raise $125 million through a public offering to support future R&D and operations, despite a GAAP EPS of -$1.06 that missed expectations, raising concerns about its financial health in the market.
- Market Evaluation: According to Seeking Alpha's Quant Rating, Zura Bio's momentum is considered real, but the successful delivery of its TibuSHIELD project remains critical, which will directly impact investor confidence in the company's future prospects.
See More
Zura Bio Reports Q1 2026 Financial Results and Updates
- Clinical Trial Progress: Zura Bio's two ongoing Phase 2 trials, TibuSHIELD and TibuSURE, are on track to report topline data in Q4 2026 and H1 2027, respectively, indicating the company's commitment to advancing its pipeline and capturing market opportunities.
- Strong Cash Position: As of March 31, 2026, Zura reported cash and cash equivalents of $225.6 million, which is expected to fund operations through at least the end of 2028, reflecting robust financial management and confidence in future growth.
- Leadership Appointments: In January 2026, Sandeep Kulkarni was appointed CEO, followed by the addition of two board members in February, enhancing the company's leadership team to drive strategic development in the biotechnology sector.
- Financial Performance: Zura reported a net loss of $24.2 million for Q1 2026, up from $17.4 million in Q1 2025, primarily due to increased R&D expenses, highlighting the ongoing investment and challenges in clinical development.
See More
